Degarelix

Overview

Degarelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist developed by Ferring Pharmaceuticals and marketed as Firmagon. It received FDA approval in December 2008 for the treatment of patients with advanced prostate cancer. Degarelix was the first injectable GnRH antagonist approved specifically for prostate cancer in the United States.

Advanced prostate cancer is predominantly androgen-dependent, with tumor growth driven by testosterone signaling through the androgen receptor. Androgen deprivation therapy (ADT) is a cornerstone of treatment, achieved either surgically (bilateral orchiectomy) or pharmacologically. GnRH agonists such as Leuprolide and Triptorelin have been the standard pharmacological approach for decades but carry the limitation of causing an initial testosterone surge (flare) during the first 1-2 weeks of treatment due to their mechanism of receptor desensitization.

Degarelix bypasses this problem entirely. As a competitive GnRH receptor antagonist, it immediately blocks GnRH signaling at the pituitary, producing rapid and profound suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone without any initial stimulatory phase.

Structure and Pharmacology

Molecular characteristics:

• Sequence: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2
• Length: 10 amino acids (decapeptide)
• Molecular weight: 1,632.3 Da
• Key features: Multiple non-natural amino acid substitutions; N-acetylated, C-amidated; five D-amino acid or modified residues — illustrating advanced peptide synthesis techniques
• Administration: Subcutaneous injection (loading dose followed by monthly maintenance)

GnRH Receptor Antagonism

The hypothalamic-pituitary-gonadal (HPG) axis regulation of testosterone production:

1. Normal physiology: Hypothalamic GnRH is released in pulsatile fashion, binding GnRH receptors on anterior pituitary gonadotroph cells, stimulating LH and FSH release. LH drives Leydig cell testosterone production in the testes.
2. GnRH agonist mechanism: Continuous agonist exposure (non-pulsatile) initially stimulates gonadotropin release (flare), then desensitizes and downregulates GnRH receptors over 2-4 weeks, eventually suppressing LH, FSH, and testosterone
3. Degarelix mechanism: Immediate competitive blockade of GnRH receptors prevents any gonadotropin release, achieving rapid testosterone suppression within 1-3 days without flare

Degarelix's non-natural amino acid residues serve dual purposes:

• Proteolytic stability: D-amino acids and bulky aromatic modifications prevent enzymatic degradation
• Receptor antagonism: The modified residues alter the peptide's interaction with the GnRH receptor, preventing the conformational change required for receptor activation while maintaining high-affinity binding

Clinical Applications

Advanced Prostate Cancer

Degarelix is used as ADT monotherapy or in combination with other prostate cancer treatments:

Dosing:

• Loading dose: 240 mg subcutaneously (administered as two 120 mg injections) on day 1
• Maintenance: 80 mg subcutaneously every 28 days, beginning 28 days after the loading dose
• Injection site: Abdominal region, with rotation between injection sites

In the pivotal Phase III trial (CS21), degarelix achieved castrate testosterone levels (< 0.5 ng/mL) within 3 days in 96% of patients, compared to a median of 28 days with leuprolide. Testosterone suppression was maintained throughout 12 months of treatment with comparable efficacy to leuprolide for PSA response.

Clinical Advantages Over GnRH Agonists

• No testosterone flare: Immediate suppression eliminates the risk of clinical flare (bone pain exacerbation, urinary obstruction, spinal cord compression) that can occur with GnRH agonists in patients with advanced or metastatic disease
• No need for anti-androgen co-treatment: GnRH agonists often require concomitant anti-androgen therapy during the first weeks to mitigate flare; degarelix does not
• Rapid onset: Castrate testosterone levels achieved within days rather than weeks
• FSH suppression: More profound FSH suppression compared to GnRH agonists, which may have implications for bone health and metabolic parameters
• PSA progression-free survival: Some analyses suggest improved PSA-PFS with degarelix, particularly in patients with baseline PSA > 20 ng/mL, though overall survival data are limited

Pharmacokinetics

Degarelix forms a gel-like depot at the subcutaneous injection site due to its amphiphilic properties at physiological pH. This depot provides sustained drug release over the dosing interval. The long effective duration from the depot allows monthly administration despite the peptide's relatively shorter inherent half-life.

Safety Profile

• Injection site reactions: The most common adverse effect (40%); manifested as pain, erythema, swelling, induration, and nodule formation at the injection site; generally mild to moderate and self-resolving
• Hot flashes: 26%, consistent with testosterone suppression (class effect of all ADT)
• Weight gain: 9-11%, common with androgen deprivation
• Fatigue: 6%
• Increased transaminases: Reported in 10% of patients; periodic liver function monitoring recommended
• QT prolongation: Androgen deprivation may prolong the QT interval; ECG consideration in patients with QT risk factors

Serious adverse effects related to long-term androgen deprivation (common to all ADT modalities) include osteoporosis, metabolic syndrome, cardiovascular events, and cognitive changes.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Degarelix (Firmagon) is an FDA-approved GnRH antagonist for advanced prostate cancer. Always consult a qualified healthcare professional.

Administration notes: Reconstitute each vial according to product instructions. Administer as deep subcutaneous injections in the abdominal area, rotating injection sites. No anti-androgen co-treatment is needed (unlike GnRH agonists) since there is no testosterone flare. Monitor testosterone and PSA levels periodically. Injection site reactions (pain, erythema, swelling) occur in approximately 40% of patients and are generally self-limiting.

Scientific Significance

Degarelix demonstrates how peptide antagonist design can overcome the pharmacological limitations of agonist-based receptor modulation. While GnRH agonists require weeks of continuous stimulation to achieve functional suppression through receptor desensitization, degarelix achieves the same endpoint within days through direct receptor blockade. The compound's extensive use of non-natural amino acids illustrates advanced peptide medicinal chemistry, where each residue substitution serves a specific pharmacological or pharmacokinetic purpose.

The clinical experience with degarelix has also influenced the development of oral GnRH antagonists (relugolix), reflecting the ongoing effort to translate the pharmacological advantages of receptor antagonism into more convenient dosing forms within the drug development pipeline.